Join our daily newsletter At The Bell to receive exclusive market insights
- Emyria (EMD) says its first batch of MDMA have demonstrated excellent purity and stability at room temperature
- Nuclear-magnetic resonance screening and high-performance liquid chromatography confirmed the findings, which are required prior to advancing the screening process
- The company says this is an important first step in its drug development program
- Further testing is being finalised for the remainder of the library, while this first batch of compounds is being prepared for neurological receptor target screening
- Emyria was in the grey, last trading at 22 cents at 12:50 pm AEST
Emyria (EMD) says its first batch of MDMA analogues have demonstrated pleasing results at room temperature.
Nuclear-magnetic resonance screening and high-performance liquid chromatography have been said confirm excellent purity and long-term stability for all compounds evaluated.
High purity and stability results are required prior to advancing the screening process.
“We’re delighted to confirm that the first batch of MDMA-analogues evaluated show excellent purity and stability,” said Emyria’s Managing Director, Dr. Michael Winlo.
“This is an important first step in our drug development program, which can now progress to comprehensive neurological receptor screening.”
The company’s comprehensive preliminary analysis has been completed on the first batch of compounds from Emyria’s exclusively optioned MDMA analogue library. These were developed at the University of Western Australia.
Emyria says a PhD qualified chemist has been appointed to manage the MDMA analogue screening program, in collaboration with UWA staff.
An initial set of neurological targets and anti-targets have also been identified in consultation with Emyria’s key clinical advisor.
“Emyria’s clinical network and data infrastructure is uniquely positioned and committed to advancing MDMA-assisted therapy in Australia, and MDMA drug development globally, to help treat a variety of major psychiatric and neurological conditions,” said Dr Winlo.
Further testing is now being finalised for the remainder of the library while this first batch of compounds is being prepared for neurological receptor target screening.
Emyria was in the grey, last trading at 22 cents at 12:50 pm AEST.
